GlobeNewswire Inc.··NaTrevi Therapeutics Raises $150M to Advance Nalbuphine Program for Chronic Cough
Trevi Therapeutics prices $150M stock offering at $13/share, raising capital for Haduvio development across chronic cough indications.
TRVIclinical-stagepublic offering